{"id":"NCT00968526","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults","officialTitle":"Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 Years and Above","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09-08","primaryCompletion":"2010-09-23","completion":"2010-09-23","firstPosted":"2009-08-31","resultsPosted":"2018-09-18","lastUpdate":"2019-06-25"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"GSK investigational vaccine GSK2340272A","otherNames":[]}],"arms":[{"label":"GSK2340272A 2D Group","type":"EXPERIMENTAL"},{"label":"GSK2340272A 1D Group","type":"EXPERIMENTAL"}],"summary":"The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.","primaryOutcome":{"measure":"Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies","timeFrame":"At Day 21","effectByArm":[{"arm":"GSK2340272A 2D (18-60y) Sub-Group","deltaMin":63,"sd":null},{"arm":"GSK2340272A 2D (>60y) Sub-Group","deltaMin":53,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":10,"exclusionCount":18},"locations":{"siteCount":1,"countries":["Belgium"]},"refs":{"pmids":["23571166","20687838"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":102},"commonTop":["Pain","Headache","Fatigue","Myalgia","Nasopharyngitis"]}}